A multi-center prospective study of re-irradiation with bevacizumab and temozolomide in patients with bevacizumab refractory recurrent high-grade gliomas.

Purpose: Survival is dismal for bevacizumab refractory high-grade glioma patients. We prospectively investigated the efficacy of re-irradiation, bevacizumab, and temozolomide in bevacizumab-naïve and bevacizumab-exposed recurrent high-grade glioma, without volume limitations, in a single arm trial.

Methods: Recurrent high-grade glioma patients were stratified based on WHO grade (4 vs.

Clinical neuro-oncology formal education opportunities for medical students in the United States and Canada.

Objective: To develop an understanding of the availability of the formal clinical neuro-oncology educational opportunities for medical students.

Methods: The curriculum websites of all medical schools accredited by the Liaison Committee on Medical Education were reviewed for the presence of clinical neuro-oncology electives as well as other relevant data.

Results: Ten (6.

Update in the treatment of high-grade Gliomas.

Advances in the molecular classification of high-grade gliomas are laying the groundwork for potential changes in the treatment of high-grade gliomas. Currently, a combined modality approach involving surgery, radiation therapy, and chemotherapy is most often used in the treatment of high-grade gliomas. The authors review recent advances in the treatment of these primary brain tumors.

Temozolomide and/or Erlotinib in the Treatment of Lung Cancer Patients With Progressive Central Nervous System Metastases.

Background: Patients with lung cancer who develop brain metastases have a poor prognosis. Those patients with progressive brain metastases tend to have a dismal prognosis. Currently, there is no standard of care for the treatment of these patients.